These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22366593)

  • 1. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
    Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.
    Thomas M; Mariani A; Wright JD; Madarek EO; Powell MA; Mutch DG; Podratz KC; Dowdy SC
    Gynecol Oncol; 2008 Feb; 108(2):293-7. PubMed ID: 18096208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
    Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
    J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
    Diaz ES; Walts AE; Karlan BY; Walsh CS
    Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.
    Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM
    Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
    Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
    Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
    Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
    Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment issues in clear cell carcinoma of the ovary: a different entity?
    Pectasides D; Pectasides E; Psyrri A; Economopoulos T
    Oncologist; 2006; 11(10):1089-94. PubMed ID: 17110628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
    Bristow RE; Duska LR; Montz FJ
    Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
    Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
    Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
    Schnack TH; Høgdall E; Nedergaard L; Høgdall C
    Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy of uterine clear cell carcinoma: a review.
    Xu Y; Hanna RK; Elshaikh MA
    Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.